Subgroup analysis of three trials (n = 1,261) [37-39] showed that G-CSF therapy was associated with a significant increase in reversal rate from infection (RR = 1.30, 95% CI: 1.07 to 1.58, P = 0.007; P for heterogeneity = 0.84, I2 = 0%). This evidence concerns the gene CSF3 and infection.